Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155

Safety, activity, and immune correlates of anti–PD-1 antibody in cancer

Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628

Safety and activity of anti-PD-L1 antibody in patients with advanced cancer

Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945

Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802

PD-1 blockade induces responses by inhibiting adaptive immune resistance

Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609

In-gel digestion for mass spectrometric characterization of proteins and proteomes

Shevchenko, A., Tomas, H., Havli, J., Olsen, J. V., & Mann, M. (2006) · Nature Protocols · doi:10.1038/nprot.2006.468 · Cited by 4,947

Protocol for micro-purification, enrichment, pre-fractionation and storage of peptides for proteomics using StageTips

Rappsilber, J., Mann, M., & Ishihama, Y. (2007) · Nature Protocols · doi:10.1038/nprot.2007.261 · Cited by 4,641

Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286

Tumor-Associated Macrophages: From Mechanisms to Therapy

Noy, R., & Pollard, J. W. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.010 · Cited by 4,089

Dual-modular-nanobody CAR-T cell technical platform against the solid tumor microenvironment

Li, Y., Wang, X., Zhang, S., Peng, T., Gong, Z., Jiang, H., Huang, X., Xie, S., Liu, H., Mo, F., et al. (2026) · Journal of Hematology & Oncology · doi:10.1186/s13045-026-01821-7 · Cited by 1

Humoral immunity in cancer

Leonard, J., Duhamel, M., & Salzet, M. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02902-2 · Cited by 2

Chimeric antigen receptor (CAR)-T cell therapy for solid tumors in pediatric patients: current breakthroughs, dilemmas, and strategies

Mai, Y., Wang, Z., Wang, J., Song, M., Xiang, T., He, Y., Chang, A. H., & Zhang, Y. (2026) · Experimental Hematology and Oncology · doi:10.1186/s40164-026-00822-z · Cited by 1

TCR-based cellular immunotherapy for hepatocellular carcinoma: advances, challenges, and prospects

Zeng, W., Zhu, W., Yuan, G., Chen, J., Wang, Z., Hou, J., & Jiang, D. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-04122-z · Cited by 2

Arming oncolytic herpes simplex virus with CXCL-11, IL-12 and a single-chain antibody against PD-1 to enhance CAR-T cell therapy in pancreatic ductal adenocarcinoma

Chen, X., Ma, W., Guan, Y., Jin, X., Yu, J., Zhang, S. M., & Zhang, N. (2026) · Cell Death and Disease · doi:10.1038/s41419-026-08695-0 · Cited by 1

Immune Checkpoint Blockade and Emerging Combination Platforms in Breast Cancer: A Narrative Review

Abbaspour, M., Esmaeil, N., Akbari, V., Ghoreishi, M., & Rafiepoor, H. (2026) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s588323 · Cited by 1

Enhancing persistence while managing cytokine release syndrome to embrace next-generation CAR-T cell therapy

Yang, Y., Sun, Y., Kang, H., Guan, E., Liu, R., Yang, K., & Jiang, D. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-08299-4 · Cited by 1

Establishment of a scalable engineered cell-line platform for direct, GMP-grade production of eVLP vectors enabling streamlined generation of gene-edited CAR-T/NK cells

Wei, L., Shi, J., Chen, H., Chai, R., Zhu, S., Chen, L., Mo, S., Wang, Z., Li, H., Feng, Y., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1878099 · Cited by 1

Off-the-Shelf Chimeric Antigen Receptor Immune Cells from Human Pluripotent Stem Cells

Cao, H., & Sugimura, R. (2022) · Cancer treatment and research · doi:10.1007/978-3-030-96376-7_9 · Cited by 1

A novel non-viral PDCD1 site-integrated CAR design: killing 2 birds with 1 stone

Cui, Y., Huang, Y., Qin, L., & Li, P. (2022) · Blood Science · doi:10.1097/bs9.0000000000000135 · Cited by 1

The “Great Debate” at Immunotherapy Bridge 2022, Naples, November 30th–December 1st, 2022

Ascierto, P. A., Brentjens, R. J., Khleif, S. N., Odunsi, K. O., Rezvani, K., Ruella, M., Sullivan, R. J., Fox, B. A., & Puzanov, I. J. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04117-3 · Cited by 1

Inflammatory microenvironment and immunotherapy in hepatocellular carcinoma

Liu, L., & Liu, B. (2023) · European Journal of Inflammation · doi:10.1177/1721727x231172025 · Cited by 1

Biosynthesis of multifunctional transformable peptides for downregulation of PD-L1

Di, Y., Yang, Z., Song, G., Shen, Q., Bai, H., Huang, Y., Lv, F., & Wang, S. (2024) · Chemical Communications · doi:10.1039/d4cc03146f · Cited by 1

CAR T cells re-directed by a rationally designed human peptide tag demonstrate efficacy in preclinical models

Knelangen, N., Bader, U., Maniaki, E., Langan, P. S., Engert, F., Drees, B., Schwarzer, J., Kotter, B., Kiefer, L., Gattinoni, L., et al. (2025) · Cytotherapy · doi:10.1016/j.jcyt.2025.03.506 · Cited by 1

Achieving stringent complete remission in relapsed/refractory multiple myeloma with liver extramedullary disease after CAR‑T cell therapy: A case report

Zhou, L., Liu, D., Du, F., Chen, J., Lu, W., Xiang, H., & Chen, H. (2025) · Oncology Letters · doi:10.3892/ol.2025.14999 · Cited by 1

Research Progress of the Treatment of PD-1 Immune CheckpointInhibitors in Oral Squamous Cell Carcinoma

Wang, Y.-T., Qian, S., & Li, K. (2020) · Journal of Oncology Research · doi:10.30564/jor.v2i2.2429 · Cited by 1

Preclinical Chimeric Antibody Chimeric Antigen Receptor T Cell Progress in Digestive System Cancers

Lü, P., Qiu, S., Pan, Y., Yu, F., & Chen, K. (2021) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2020.4089 · Cited by 1

A novel gene signature based on five immune checkpoint genes predicts the survival of glioma

Zhang, W., Zhai, Y., Li, G., & Jiang, T. (2021) · Chinese Neurosurgical Journal · doi:10.1186/s41016-020-00220-2 · Cited by 1

Recent progress in research and application of engineered implanted cells for biomedical applications

Chen, T., Zhang, X., & Wu, Q. (2021) · Quantitative Biology · doi:10.15302/j-qb-021-0253 · Cited by 1

Optimizing the role of immunotherapy for the treatment of glioblastoma

Cascão, R., & Faria, C. C. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99873-4.00012-8 · Cited by 1

convertible CARs: A chimeric antigen receptor system for flexible control of activity and antigen targetingPreprint

Landgraf, K. E., Williams, S. R., Steiger, D., Gebhart, D., Lok, S., Martin, D. W., Roybal, K. T., & Chan, K. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/696401 · Cited by 1

Special delivery by “armored” CAR-T

Jay, S. M. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aav0334

When a CAR becomes a tank

Villanueva, M. T. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.164

Chimeric antigen receptors: Leading the next frontier of anti-cancer therapy

Leyfman, Y. (2018) · Trends in Research · doi:10.15761/tr.1000114

Immune checkpoint modulation: Tenets and implications in glioblastoma

Nduom, E. K.-E., Lynes, J. P., Sánchez, V., Nwankwo, A., & Dominah, G. A. (2019) · Glioma · doi:10.4103/glioma.glioma_47_18

Updates and rationale of clinical trials in multiple myeloma

Branagan, A. R., Lei, M. M., Tracey, C., & Raje, N. S. (2019) · Advances in Cell and Gene Therapy · doi:10.1002/acg2.59

Future prospects of chimeric antigen receptor T‐cell therapy for multiple myeloma

de Larrea, C. F., Mailankody, S., Landgren, O., & Smith, E. L. (2019) · Advances in Cell and Gene Therapy · doi:10.1002/acg2.72

Combination Therapies in Solid Tumour Oncology

Vertès, A. A. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-812034-7.00020-0 · Cited by 1

[Mechanisms and countermeasures in relapse of relapsed/refractory non-Hodgkin lymphoma after treatment of CD19 chimeric antigen receptor T cells].

Wang, S. Y., Cao, J., & Xu, K. (2020) · PubMed Central · doi:10.3760/cma.j.issn.0253-2727.2020.05.017

A Phase 1 Dose Escalation Trial of Third Generation Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed and Refractory B-Cell Non Hodgkin Lymphoma

George, P. (2020) · Open Access Victoria University of Wellington | Te Herenga Waka (Figshare) · doi:10.26686/wgtn.17148182.v1

Proceedings From the First International Workshop at Sidra Medicine: “Engineered Immune Cells in Cancer Immunotherapy (EICCI): From Discovery to Off-the-Shelf Development”, 15th–16th February 2019, Doha, Qatar

Guerrouahen, B. S., Elnaggar, M., Al-Mohannadi, A., Kizhakayil, D., Bonini, C., Benjamin, R., Brentjens, R. J., Buchholz, C. J., Casorati, G., Ferrone, S., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.589381

Construction of PD1/CD28 Fusion Receptor Enhances Anti-Tumor Ability of c-Met CAR-T in Gastric CancerPreprint

Chen, C., Gu, Y., Zhang, Z., Zhang, Y., He, Y.-D., Tang, F., Liu, H., & Li, Y. (2020) · SSRN Electronic Journal · doi:10.2139/ssrn.3738093

旅行ランナーの健康と安全を考える--トレイルランニングレースにおけるAED(自動体外式細動器)システムの必要性

中山, 三. (2007) · Institutional Repositories DataBase (IRDB)

Progress of CAR-T Therapy in Gastric Cancer

李, 桃. (2022) · Advances in Clinical Medicine · doi:10.12677/acm.2022.124361

Chimeric antigen receptor engineered cells and their clinical application in infectious disease

Chen, Q., Bo, X., Hao, J., Wang, Z., & Li, B. (2022) · Clinical and Translational Discovery · doi:10.1002/ctd2.129

Clinical application of cell‐based therapies opportunities and challenges

Gao, J., & Wu, D. (2022) · Clinical and Translational Discovery · doi:10.1002/ctd2.110

T Cell Immunotherapy of Cancer

Palomba, M. L., Park, J. H., & Brentjens, R. J. (2022) · Holland‐Frei Cancer Medicine · doi:10.1002/9781119000822.hfcm067.pub3

[Relapse mechanism and coping strategies of CD19 chimeric antigen receptor T cells in the treatment of diffuse large B-cell lymphoma].

Zhang, Q., & Xiao, Y. (2022) · PubMed Central · doi:10.3760/cma.j.issn.0253-2727.2022.09.014

Matching-Adjusted Indirect Comparisons Applied for Comparative Efficacy of Haematologic Cancer Drugs within Health Economic Analysis

Muresan, B. (2023) · doi:10.33612/diss.568330158

T-cell engineering strategies for tumors with low antigen density, and T-cell survival in the immunosuppressive tumor microenvironment of relapsed/refractory diffuse large B-cell lymphoma

Luan, R., & Deng, B. (2023) · Hematology and Oncology Discovery · doi:10.15212/hod-2022-0009

Data from CRISPR Screening of CAR T Cells and Cancer Stem Cells Reveals Critical Dependencies for Cell-Based Therapies

Wang, D., Prager, B. C., Gimple, R. C., Aguilar, B., Alizadeh, D., Tang, H., Lv, D., Starr, R., Brito, A., Wu, Q., et al. (2023) · doi:10.1158/2159-8290.c.6549389.v1

Supplementary Table 2 from CRISPR Screening of CAR T Cells and Cancer Stem Cells Reveals Critical Dependencies for Cell-Based Therapies

Wang, D., Prager, B. C., Gimple, R. C., Aguilar, B., Alizadeh, D., Tang, H., Lv, D., Starr, R., Brito, A., Wu, Q., et al. (2023) · doi:10.1158/2159-8290.22540475.v1

Data from Siglec-15 Promotes Evasion of Adaptive Immunity in B-cell Acute Lymphoblastic Leukemia

Pillsbury, C. E., Dougan, J., Rabe, J. L., Fonseca, J. A., Zhou, C., Evans, A. N., Abukharma, H., Ichoku, O., Gonzalez-Flamenco, G., Park, S. I., et al. (2023) · doi:10.1158/2767-9764.c.6710729

The Future of Chimeric Antigen Receptor T Cell Therapy

Smith, E. L. (2023) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2023.06.005

Molecular docking studies on the interaction of phytocompounds exploring the antifungal potency against Candida spp.

George, S. A., & Bhadran, S. (2023) · doi:10.22192/ttdls.2023.007

Value Added Products from Mushroom – Need for the Hour

Pallavi, E., & Sheeba, E. (2023) · doi:10.22192/ttdls.2023.001

Role of diet and Nutrition in Enhancing sporting performance

Vijayanand, D. S. (2023) · doi:10.22192/ttdls.2023.008

Phytochemicals and their Functional Aspects

Ramojwar, J. (2023) · doi:10.22192/ttdls.2023.005

Nano bio-pesticides in sustainable agriculture

Deepa, V. H., & Prakash, N., V (2023) · doi:10.22192/ttdls.2023.006

A Molecular Approach of Signaling Molecules, Its Receptors and Their Responses

Dr. Malathi, R. (2023) · doi:10.22192/ttdls.2023.002

Bioplastics – A boon or curse

Deepa, V. H. (2023) · doi:10.22192/ttdls.2023.003

Medicinal potential of Fabaceae family members

Lama, S. (2023) · doi:10.22192/ttdls.2023.014

Application of Artificial Intelligence in Biochemistry

Inbavalli., K. (2023) · doi:10.22192/ttdls.2023.015

Detection of heavy metals in plants and its impact on environment

Babu, B. (2023) · doi:10.22192/ttdls.2023.012

Enhancing the Sustainability and Performance of Bio-Concrete: A Comprehensive Review of Microbial- Based Construction Materials

Ekanayake, A. K., Ekanayake, A. K., & Gupta, N. (2023) · doi:10.22192/ttdls.2023.009

A Description of Chimeric Antigen ReceptorModified T Cells in Cancer Immunotherapy

Xu, X., Xiang, Y., Yang, Y., Cui, Z., Wang, M., Yanhong, G., & Huang, J. (2023) · Journal of Oncology Research and Therapy · doi:10.29011/2574-710x.10187

Immuntherapie mit CAR-T-Zellen: der Durchbruch in der Krebsbehandlung

Harrer, D. C., & Abken, H. (2023) · Springer eBooks · doi:10.1007/978-3-662-67908-1_10

T cell exhaustion and challenges of CAR-T cell therapy for solid tumors

Kuramitsu, S., Yamaguchi, J., Nohira, S., Ohno, M., Fujita, M., & Saito, R. (2024) · Japanese Journal of Transplantation and Cellular Therapy · doi:10.7889/tct-23-029

The Spectrum of CAR T Assets in Development: Similarities and Differences

Haydu, J. E., & Abramson, J. S. (2024) · Wiley eBooks · doi:10.1002/9781119824572.ch21

Terapia de células adoptivas en cáncer de mama

Oliva, B. G. M., & Jiménez, M. P. Z. (2021) · Orbis Tertius - UPAL · doi:10.59748/ot.v5i9.93

Cancer Immunotherapy: A Systemic Review

Bokshi, S. K., Biswas, K. R., & Chowdhury, A. K. (2024) · Archives of Oncology and Cancer Therapy · doi:10.22259/2638-5074.0401004

Additional file 6 of Contextual reprogramming of CAR-T cells for treatment of HER2+ cancers

Yang, Z., Li, L., Turkoz, A., Chen, P., Harari-Steinfeld, R., Bobbin, M. L., Stefanson, O., Choi, H., Pietrobon, V., Alphson, B., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16946374

The Evolution and Future of CAR T-Cell Therapy in Cancer Treatment

Shakthivel, C. D. (2024) · Advances in medical diagnosis, treatment, and care (AMDTC) book series · doi:10.4018/979-8-3693-7728-4.ch008

Combination of CAR T cell therapies with immune checkpoint inhibitors

Lin, H. K., Blake, D. A., & Rafiq, S. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-14064-8.00040-0

Metabolic Regulation of CAR-T Cell Function by Hypoxic Tumor

Pathak, T., Ray, S. K., & Mukherjee, S. (2025) · Springer eBooks · doi:10.1007/978-981-96-1016-7_5

Gene Therapy Against Age-Related Diseases

Rai, R. R., Barage, S. H., & Singh, R. (2025) · IGI Global eBooks · doi:10.4018/979-8-3693-9730-5.ch005

Cell therapy in pediatric blood diseases

Romo‐Rodríguez, R., Pelayo, R., & Ramírez-Ramírez, D. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1591287

Development of a Gene Editing Platform to Enhance CAR-T Therapy Through Inducible IL-15 Expression at the PD-1 LocusPreprint

Cortijo-Gutierréz, M., Maldonado‐Pérez, N., Tristán‐Manzano, M., Pavlovic, K., Justicia-Lirio, P., Fuster‐García, C., Cathomen, T., Bak, R. O., Jurado-Bascón, P. P., Carmona‐Sáez, P., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-7012598/v1

Optimizing CAR-T Therapy through CRISPR technology

Liu, Y. (2025) · Transactions on Materials Biotechnology and Life Sciences · doi:10.62051/ma2f5v65

MicroRNA-Orchestrated Modulation of CAR-T Cells: Overcoming Functional Barriers Toward Next-Generation Immunotherapy

Sadri, F., & Rezaei, Z. (2025) · Journal of Cancer Biomoleculars and Therapeutics · doi:10.62382/jcbt.v2i4.77

Response-Based Immunotherapy in Melanoma

Bushara, O., Farooq, M. S., Vargas, G. M., & Karakousis, G. C. (2025) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2025.10.002

Integration of a novel anti-PD-1 antibody with chimeric antigen receptor-T engineered to express interleukin-7 enhances targeting efficacy against lung cancer

Cheng, C., Zhang, L., Cao, J., Li, X., Wen, Y., Liu, K., & Zhao, T. (2025) · Life Medicine · doi:10.1093/lifemedi/lnaf035

Blockade of co-inhibitory receptor immune checkpoint protein TIM3/CD366 augments the anti-cancer activity of CAR-T therapy in solid tumors: An ovarian cancer example

Zhang, B., Zhu, F., Wang, S., Huang, Y., Yu, S., Tian, S., Li, M., Pan, L., Xue, Q., & Zhang, B. (2025) · Genes & Diseases · doi:10.1016/j.gendis.2025.101978

Additional file 4 of A novel gene signature based on five immune checkpoint genes predicts the survival of glioma

Zhang, W., Zhai, Y., Li, G., & Jiang, T. (2021) · Figshare · doi:10.6084/m9.figshare.13698443

Additional file 3 of A novel gene signature based on five immune checkpoint genes predicts the survival of glioma

Zhang, W., Zhai, Y., Li, G., & Jiang, T. (2021) · Figshare · doi:10.6084/m9.figshare.13698440

Additional file 1 of Inducible localized delivery of an anti-PD-1 scFv enhances anti-tumor activity of ROR1 CAR-T cells in TNBC

Harrasser, M., Gohil, S. H., Lau, H. E., Peruta, M. D., Muczynski, V., Patel, D., Miranda, E., Grigoriadis, K., Grigoriadis, A. E., Granger, D., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20001204

Additional file 2 of A novel gene signature based on five immune checkpoint genes predicts the survival of glioma

Zhang, W., Zhai, Y., Li, G., & Jiang, T. (2021) · Figshare · doi:10.6084/m9.figshare.13698437

Additional file 1 of Contextual reprogramming of CAR-T cells for treatment of HER2+ cancers

Yang, Z., Li, L., Turkoz, A., Chen, P., Harari-Steinfeld, R., Bobbin, M. L., Stefanson, O., Choi, H., Pietrobon, V., Alphson, B., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16946356

Additional file 1 of Target delivery of a PD-1-TREM2 scFv by CAR-T cells enhances anti-tumor efficacy in colorectal cancer

Chen, J., Zhu, T., Jiang, G., Zeng, Q., Li, Z., & Huang, X. (2023) · Figshare · doi:10.6084/m9.figshare.23930323

Additional file 4 of Contextual reprogramming of CAR-T cells for treatment of HER2+ cancers

Yang, Z., Li, L., Turkoz, A., Chen, P., Harari-Steinfeld, R., Bobbin, M. L., Stefanson, O., Choi, H., Pietrobon, V., Alphson, B., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16946368

Additional file 1 of A novel gene signature based on five immune checkpoint genes predicts the survival of glioma

Zhang, W., Zhai, Y., Li, G., & Jiang, T. (2021) · Figshare · doi:10.6084/m9.figshare.13698434

Additional file 1 of Dual-binding nanoparticles improve the killing effect of T cells on solid tumor

Luo, Z., Luo, L., Lu, Y., Zhu, C., Qin, B., Jiang, M., Li, X., Shi, Y., Zhang, J., Liu, Y., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20026278

Additional file 2 of Contextual reprogramming of CAR-T cells for treatment of HER2+ cancers

Yang, Z., Li, L., Turkoz, A., Chen, P., Harari-Steinfeld, R., Bobbin, M. L., Stefanson, O., Choi, H., Pietrobon, V., Alphson, B., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16946359

Additional file 1 of Advances in drug development for hepatocellular carcinoma: clinical trials and potential therapeutic targets

Luo, X.-Y., Wu, K.-M., & He, X.-X. (2021) · Figshare · doi:10.6084/m9.figshare.14615275

Additional file 5 of Contextual reprogramming of CAR-T cells for treatment of HER2+ cancers

Yang, Z., Li, L., Turkoz, A., Chen, P., Harari-Steinfeld, R., Bobbin, M. L., Stefanson, O., Choi, H., Pietrobon, V., Alphson, B., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16946371

Additional file 3 of Contextual reprogramming of CAR-T cells for treatment of HER2+ cancers

Yang, Z., Li, L., Turkoz, A., Chen, P., Harari-Steinfeld, R., Bobbin, M. L., Stefanson, O., Choi, H., Pietrobon, V., Alphson, B., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16946365

Safety and effectiveness of lisocabtagene maraleucel following PD-1 blockade in relapsed or refractory PMBCL

Yamaguchi, K., Yamauchi, T., Hirakawa, S., Nakagaki, H., Nishihara, H., Shimo, M., Sasaki, K., Sakoda, T., Jinnouchi, F., Miyawaki, K., et al. (2026) · International Journal of Hematology · doi:10.1007/s12185-025-04148-0

Systemtherapien der Zukunft: CAR-T-Zellen

Müller, F., Hoerster, K., & von Tresckow, B. (2026) · Forum · doi:10.1007/s12312-025-01524-z

Non-human primate preclinical model revealed the feasibility and short-term safety of iPSC-derived innate-like T cells in autologous transplantation

Miyake, Y., Iriguchi, S., Kawana‐Tachikawa, A., Kitayama, S., Imai, E., Taya, K., Ishii, H., Miura, T., Sakawaki, H., Matano, T., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1653275

CAR T cell therapy for fighting IPF: perspectives on a living drug

Sun, W., Lu, S., Chen, T., He, Y., Xu, Z., & Cai, Z. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1770081 · Cited by 1

Efficacy and safety of zanubrutinib and camrelizumab combined with CD19 chimeric antigen receptor T-cell in the treatment of relapsed/refractory diffuse large B-cell lymphoma

Zhang, H., He, X., Xiao, X. Y., Ly, H., & Zhao, M. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1766905

Decoding the cellular interactions regulating CAR T cell antitumor activity in vivo using two-photon intravital imaging

Cazaux, M. (2020) · theses.fr (ABES) · doi:10.70675/1a85e1e6zff4cz4922z890fz5d03771de69c

Optimisation des approches de transfert adoptif de lymphocytes T dans le mélanome : édition des gènes codant pour les immune checkpoints et combinaison thérapeutique

Marotte, L. (2021) · theses.fr (ABES) · doi:10.70675/00bc5405z4e6bz40c1z8dc2zccbee0116d94

Comprendre et cibler la molécule intracellulaire "CISH" dans les cellules Natural Killer : une stratégie pour optimiser les traitements en immunothérapies

Bernard, P.-L. (2023) · theses.fr (ABES) · doi:10.70675/b8c6e6e6z06f4z4377z80e6z1bce4ed7771a

The gut microbiota as a modulator of CAR T cells therapy efficacy : role for Akkermansia supplementation via the AhR pathway

Marcos-Kovandzic, L. (2024) · theses.fr (ABES) · doi:10.70675/3bde4b45z23ecz4b69zb90dzabccd7cd7fca

Immunomodulation des lymphocytes Vγ9Vδ2 dans les leucémies aigües

Floch, A.-C. L. (2023) · theses.fr (ABES) · doi:10.70675/b4e332efz0a66z4c9az85eaz8eea012e9839

PD-L1-armored CD19/CD22 dual-targeted CAR-T cell co-infusion bridging to allogeneic hematopoietic stem cell transplantation achieves 7-year sustained remission in an adult patient with early relapsed, chemorefractory B-cell acute lymphoblastic leukemia: a case report

Hua, H., Wen, S., Han, X., Liu, X., Zhou, Z., Song, Z., Zhang, X., & Wang, F. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1797562

Chimeric Antigen Receptor T Cells as Living Therapeutics Targeting Senescence and Age-Related Diseases

Shao, Q., Chen, D., Shao, W., & Ye, Q. (2026) · Research · doi:10.34133/research.1326 · Cited by 1

Fundamentals of engineered T cell therapies: From basic design to bells and whistles

Minehart, J. C., Cross, E. W., Oo, P. S., & Bhoj, V. G. (2026) · Advances in pharmacology · doi:10.1016/bs.apha.2026.05.002

Discovery 4.0: An Escape-Aware Computational Platform for Resistance-Proofed Chimeric Antigen Receptor DesignPreprint

Daneshvar, A., Mashayekhi, R., & Sharifnia, M. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.24.727464

Abstract 2568: CAR T cells secreting an immune checkpoint blockade scFv have enhanced anti-tumor efficacy

Rafiq, S., Yeku, O., Jackson, H. J., Purdon, T. J., van Leeuwen, D. G., Yan, S., Wang, P., Xiang, J., Liu, C., Seshan, V., et al. (2018) · Cancer Research · doi:10.1158/1538-7445.am2018-2568

Enhancing CAR T Cell Anti-Tumor Efficacy through Secreted Single Chain Variable Fragment (scFv) Immune Checkpoint Blockade

Rafiq, S., Jackson, H. J., Yeku, O., Purdon, T. J., van Leeuwen, D. G., Curran, K. J., Ahmed, R. N., Cullen, G. D., Yan, S., Wang, P., et al. (2017) · Blood · doi:10.1182/blood.v130.suppl_1.842.842 · Cited by 6

Augmenting the Effectiveness of CAR-T Cells by Enhanced Self-Delivery of PD-1-Neutralizing scFv

Yü, P., Li, F., Nan, S., Zhang, D., Shi, X., Shan, J., & Zhang, Y. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00803 · Cited by 51

PD-1–Blocking scFV–Secreting CAR T Cells Exhibit Antitumor Efficacy

(2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-rw2018-143

Improved survival of chimeric antigen receptor‐engineered T ( CAR ‐T) and tumor‐specific T cells caused by anti‐programmed cell death protein 1 single‐chain variable fragment‐producing CAR ‐T cells

Nakajima, M., Sakoda, Y., Adachi, K., Nagano, H., & Tamada, K. (2019) · Cancer Science · doi:10.1111/cas.14169 · Cited by 53